Analyst thinks PHM will post Adjusted EBITDA of $7.7-million on revenue of $138.8-million in fiscal 2016
Plans to spin off its business into separate equipment and service concerns have given Patient Home Monitoring (CVE:PHM) a bump in its share price, but Mackie Research Capital analyst Russell Stanley thinks the stock still has boatloads of upside.
Patient Home Monitoring announced recently that its board had approve plans to split the company into two units, one that would be made up of the company’s interests in respiratory disease solutions and the other focused on medical equipment. Management says it expects the two companies will have separate TSX Venture exchange listings by year’s end.
Related: Patient Home Monitoring (CVE:PHM) – From Darling to Dust, But Could Times Be Changing?
Stanley thinks PHM will post Adjusted EBITDA of $7.7-million on revenue of $138.8-million in fiscal 2016, numbers he expects will climb to EBITDA of $27.3-million on revenue of $149.5-million.
Read the full article at: www.cantechletter.com
